Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 3/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 2/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5506973 | 0.94 | RAPGEF4 (0.39) | RAPGEF4CA12CA1CA9TSHR | |
| SCHEMBL16181574 | 0.84 | RAPGEF4 (0.48) | RAPGEF4EGFRHDAC3HDAC1HDAC2 | |
| SCHEMBL5514489 | 0.82 | CA12 (0.55) | RAPGEF4CA12CA1CA9APP | |
| SCHEMBL5506948 | 0.82 | HTR6 (0.36) | RAPGEF4TSHR | |
| SCHEMBL1638576 | 0.82 | RAPGEF4 (0.53) | RAPGEF4 | |
| SCHEMBL24594971 | 0.82 | RAPGEF4 (0.33) | RAPGEF4 | |
| SCHEMBL24807015 | 0.82 | RAPGEF4 (0.33) | RAPGEF4 | |
| SCHEMBL19089348 | 0.82 | HTR6 (0.39) | RAPGEF4 | |
| SCHEMBL29909475 | 0.82 | HTR6 (0.39) | RAPGEF4 | |
| SCHEMBL25005829 | 0.78 | MEN1 (0.35) | RAPGEF4KIF11EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103360312-A | Geldanamycin derivative and its application | UNIV SHANDONG | 2013-10-23 | — | — | CN | claimed |
| US-7943605-B2 | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses | UCB PHARMA S.A. (BE) | 2011-05-17 | — | — | US | claimed |
| US-20090023708-A1 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-22 | — | — | US | claimed |
| EP-1943217-A1 | COMPOUNDS COMPRISING A LACTAM OR A LACTAM DERIVATIVE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2008-07-16 | — | — | EP | claimed |
| WO-2007048595-A1 | COMPOUNDS COMPRISING A LACTAM OR A LACTAM DERIVATIVE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA, S.A. (BE) | 2007-05-03 | — | — | WO | claimed |
| EP-3600294-B1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025107026-A1 | TSPO LIGANDS | THE UNIVERSITY OF SYDNEY (AU) | 2025-05-30 | — | — | WO | disclosed |
| US-20240383885-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | MAKSCIENTIFIC, LLC | 2024-11-21 | — | — | US | disclosed |
| US-12054480-B2 | Compounds for treating cannabinoid toxicity and acute cannabinoid overdose | MAKSCIENTIFIC, LLC (US) | 2024-08-06 | — | — | US | disclosed |
| CN-117500795-A | Receptor interacting protein 1 inhibitor, preparation and application thereof | 维泰瑞隆有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117466803-A | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117412952-A | METAP-2 inhibitors, pharmaceutical compositions and methods of treatment thereof | 康崴新药有限公司 | 2024-01-16 | — | — | CN | disclosed |
| EP-1633748-B1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-03-05 | — | — | EP | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| WO-2007048595-A1 | COMPOUNDS COMPRISING A LACTAM OR A LACTAM DERIVATIVE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA, S.A. (BE) | 2007-05-03 | — | — | WO | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| WO-2007025307-A2 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383885-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | CNR1, CNR2, OPRM1 | RAPGEF4 3455/4885CA12 3857/4885CA1 3370/4885 |
| US-20090023708-A1 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses | COASY, FURIN, PEPD | RAPGEF4 3259/4885CA12 1881/4885CA1 3317/4885 |
| US-12054480-B2 | Compounds for treating cannabinoid toxicity and acute cannabinoid overdose | CNR1, CNR2, OPRM1 | RAPGEF4 3455/4885CA12 3857/4885CA1 3370/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | RAPGEF4 366/4885CA12 4618/4885CA1 4500/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | RAPGEF4 366/4885CA12 4618/4885CA1 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.